3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow ACT-1004-1239: new trials by email Literature Review of ACT-1004-1239 trials Research Report on ACT-1004-1239
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single Dose of 10 mg to Healthy Male Subjects ACT-1004-1239 (10 mg), Itraconazole (200 mg, o.d.) - Healthy | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 16 | 2022-10-01 | 2022-11-08 |
| Study in Healthy Subjects to Examine the Safety and Tolerability of ACT-1004-1239 Given as Multiple, Gradually Increasing Doses and to Examine the Effects of ACT-1004-1239 on the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-1004-1239 ACT-1004-1239, Placebo - Healthy | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 50 | 2020-07-11 | 2021-01-20 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects ACT-1004-1239, Placebo, ACT-1004-1239 (Food-effect subpart) - Healthy | Phase 1 | Completed | Idorsia Pharmaceuticals Ltd. | 64 | 2019-03-25 | 2020-01-10 |
Idorsia Pharmaceuticals Ltd. (3)
Portugal (2) · United States (1)
PMID 33595155, PMID 35431953, PMID 39010703
2019 (1)